Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma: Protocol for a Pilot Randomized Controlled Trial (Preprint)
Preprint
- 13 February 2025
- preprint
- Published by JMIR Publications Inc. in JMIR Preprints
Abstract
BACKGROUND Urothelial carcinoma is one of the most commonly diagnosed cancers worldwide, with a poor 5-year survival rate. As genomics is the backbone of the precision medicine paradigm, the genetic signature in circulating tumor DNA (ctDNA) is emerging as a pivotal biomarker for detecting early-stage cancer and molecular residual disease (MRD). OBJECTIVE We aim to evaluate the feasibility and preliminary effects of a ctDNA-based sequencing approach for detecting MRD and guiding adjuvant chemotherapy in postoperative urothelial carcinomas. METHODS We will perform a stratified 2-arm pilot randomized controlled trial in 2 tertiary hospitals in Hong Kong, involving patients with urothelial carcinomas (pT2-4a N0-2 M0) undergoing radical resection. We plan to recruit 20 patients and determine stratification according to their MRD status before randomization. Patients in each stratum (MRD-positive and MRD-negative groups) will be randomly allocated to either a 4-cycle gemcitabine plus cisplatin chemotherapy arm or a standard management arm in a 1:1 ratio. ctDNA MRD will be tested using a personalized next-generation sequencing panel, which is designed based on the individual’s whole exome sequencing results from the operation specimen. The primary outcome is the feasibility of this trial (ie, recruitment, retention, adherence, and completeness). The secondary outcome is treatment-related adverse events. Exploratory outcomes include radiographic disease-free survival, cancer-specific survival, overall survival, ctDNA clearance in patients with ctDNA MRD-positive status, quality of life, fear of cancer recurrence, and cost-effectiveness. Benchmarks for feasibility evaluation are set as (1) ≥20% recruitment response rate, (2) ≤20% loss to follow-up or withdrawal, (3) ≥80% intervention adherence, and (4) ≤20% missing value rate. Each benchmark will be assigned one score, and a total score of 4, 2 to 3, and 0 to 1 will be deemed high, medium, and low feasibility, respectively. Safety evaluations will be presented as numbers and proportions of the adverse events. ANOVA and the Kruskal-Wallis test will be used for continuous outcome variables, whereas the chi-square test and the Fisher exact test will be used for categorical outcome variables. Hazard ratios will be calculated to compare the preliminary treatment effect of the gemcitabine plus cisplatin arm against the standard management arm on survival within each MRD group. RESULTS This project was funded in February 2024. Patient recruitment started on May 2, 2024. Recruitment and data collection for the trial are ongoing. Data analysis will be performed in mid-2025 and the results of this study are expected to be published in late 2025. CONCLUSIONS Genetic signature in ctDNA is informative for personalized management of postoperative urothelial carcinomas, including personalized treatment and early detection of disease progression. CLINICALTRIAL ClinicalTrials.gov NCT06257017; https://clinicaltrials.gov/study/NCT06257017 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/72597Keywords
All Related Versions
- Published version: JMIR Research Protocols, 14 (1), e72597.
This publication has 24 references indexed in Scilit:
- Re: Bernadett Szabados, Mark Kockx, Zoe June Assaf, et al. Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder. Eur Urol 2022;82:212–22European Urology, 2022
- Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon CancerNew England Journal of Medicine, 2022
- Using Circulating Tumor DNA To Guide Adjuvant Therapy in Bladder Cancer: IMvigor010 and IMvigor011European Urology Focus, 2022
- ctDNA guiding adjuvant immunotherapy in urothelial carcinomaNature, 2021
- Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal CancerJAMA Oncology, 2019
- Validity and performance of the Functional Assessment of Cancer Therapy-Bladder (FACT-Bl) among advanced urothelial cancer patientsSupportive Care in Cancer, 2019
- Circulating tumor DNA and liquid biopsy: opportunities, challenges, and recent advances in detection technologiesLab on a Chip, 2018
- Re: Morgan Rouprêt, Marko Babjuk, Eva Compérat, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update. Eur Urol 2015;68:868–79European Urology, 2016
- A simple formula for the calculation of sample size in pilot studiesJournal of Clinical Epidemiology, 2015
- Fear of Cancer Recurrence Inventory: development and initial validation of a multidimensional measure of fear of cancer recurrenceSupportive Care in Cancer, 2008